Implications of SMAD4 Genetic Status in Recurrent Pancreatic Adenocarcinoma

被引：0
|
作者：
AlMasri, S. S. [1 ]
Zenati, M. [1 ]
Singhi, A. D. [1 ]
Lee, K. K. [1 ]
Bahary, N. [1 ]
Bartlett, D. [1 ]
Zureikat, A. [1 ]
机构：
[1] Univ Pittsburgh, Med Ctr, Surg Oncol, Pittsburgh, PA USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2020年 / 27卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
71
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [21] SMAD4 and its role in pancreatic cancer
    Xia, Xiang
    Wu, Weidong
    Huang, Chen
    Cen, Gang
    Jiang, Tao
    Cao, Jun
    Huang, Kejian
    Qiu, Zhengjun
    TUMOR BIOLOGY, 2015, 36 (01) : 111 - 119
  • [22] Correlation of Smad4 Status With Outcomes in Patients Receiving Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy After Resection for Pancreatic Adenocarcinoma
    Herman, Joseph M.
    Fan, Katherine Y.
    Wild, Aaron T.
    Wood, Laura D.
    Blackford, Amanda L.
    Donehower, Ross C.
    Hidalgo, Manuel
    Schulick, Richard D.
    Edil, Barish H.
    Choti, Michael A.
    Hruban, Ralph H.
    Pawlik, Timothy M.
    Cameron, John L.
    Laheru, Daniel A.
    Iacobuzio-Donahue, Christine A.
    Wolfgang, Christopher L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (03): : 458 - 459
  • [23] The Over-Expression of Prion Protein Associated with Loss of SMAD4 in Pancreatic Ductal Adenocarcinoma
    Zhang, L.
    Xin, W.
    MODERN PATHOLOGY, 2009, 22 : 326A - 326A
  • [24] SMAD4 Immunohistochemical Expression Loss in Esophageal Adenocarcinoma
    Waters, Kevin
    Eze, Ogechzikwu Pearl
    Pezhouh, Maryam
    Tarabishy, Yaman
    Voltaggio, Lysandra
    Montgomery, Elizabeth A.
    LABORATORY INVESTIGATION, 2017, 97 : 205A - 206A
  • [25] SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma
    Fei, Naomi
    Wen, Sijin
    Ramanathan, Rajesh
    Hogg, Melissa E.
    Zureikat, Amer H.
    Lotze, Michael T.
    Bahary, Nathan
    Singhi, Aatur D.
    Zeh, Herbert J.
    Boone, Brian A.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (05): : 1822 - 1829
  • [26] Impact of SMAD4 loss in patients with pancreatic ductal adenocarcinoma receiving neoadjuvant therapy.
    Racu, Marie-Lucie
    Bernardi, Dana
    Chaouche, Aniss
    Zindy, Egor
    Navez, Julie
    Loi, Patrizia
    Maris, Calliope
    Closset, Jean
    Van Laethem, Jean-Luc
    Decaestecker, Christine
    Salmon, Isabelle
    D'Haene, Nicky
    CANCER RESEARCH, 2022, 82 (22) : 86 - 86
  • [27] The Over-Expression of Prion Protein Associated with Loss of SMAD4 in Pancreatic Ductal Adenocarcinoma
    Zhang, L.
    Xin, W.
    LABORATORY INVESTIGATION, 2009, 89 : 326A - 326A
  • [28] Correlation of SMAD4 mutational status and local or metastatic progression in patients with pancreatic cancer
    Derbel, Olfa
    de la Fouchardiere, Arnaud
    Peron, Julien
    Rivoire, Michel
    Desseigne, Francoise
    Meeus, Pierre
    Peyrat, Patrice
    Heudel, Pierre
    Stella, Mattia
    Racadot, Severine
    DE LA Fouchardiere, Christelle
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [29] SMAD4 deficient pancreatic adenocarcinoma are poor prognosis tumours associated with histopathological aggressive features
    Fenouil, T.
    Caligaris, C.
    Bertrand, A.
    Santis, S.
    Bartholin, L.
    Hervieu, V.
    VIRCHOWS ARCHIV, 2019, 475 : S21 - S21
  • [30] SMAD4 Immunohistochemical Expression Loss in Esophageal Adenocarcinoma
    Waters, Kevin
    Eze, Ogechukwu Pearl
    Pezhouh, Maryam
    Tarabishy, Yaman
    Voltaggio, Lysandra
    Montgomery, Elizabeth A.
    MODERN PATHOLOGY, 2017, 30 : 205A - 206A
12345